136013-76-8

Usage

Uses

Used in Pharmaceutical Industry:
2-(CyclopropylMethoxy)-benzoic acid is utilized as a key intermediate in the synthesis of pharmaceutical compounds for various therapeutic applications. Its unique structure allows for the development of new drugs with improved efficacy and selectivity.
Used in Medicinal Chemistry Research:
As a chemical compound with potential biological activities, 2-(CyclopropylMethoxy)-benzoic acid is employed as a starting material in medicinal chemistry research. It aids in the discovery and optimization of novel drug candidates with enhanced pharmacological properties.
Used in Drug Development:
2-(CyclopropylMethoxy)-benzoic acid is used as a building block in the development of complex molecules with therapeutic potential. Its incorporation into larger molecular frameworks can lead to the creation of new drugs with improved pharmacokinetic and pharmacodynamic profiles.
Overall, 2-(CyclopropylMethoxy)-benzoic acid is an intriguing and significant chemical compound with a wide range of potential applications in the pharmaceutical and medicinal chemistry fields. Its unique structure and properties make it a valuable asset for the advancement of drug discovery and development efforts.

Upstream product

• 118-61-6 2-hydroxy-benzoic acid ethyl ester 
• 69-72-7 salicylic acid 
• 119-36-8 methyl salicylate 
• 6282-42-4 methyl 2-allyloxybenzoate 
• 25755-06-0 methyl 2-(cyclopropylmethoxy)benzoate 
• 148215-76-3 ethyl 2-(cyclopropylmethoxy)benzoate 

Downstream Products

• 1260527-45-4 (+/-)-(5-((5-chloropyridin-2-ylamino)methyl)-6-azaspiro[2.5]octan-6-yl)(2-(cyclopropylmethoxy)phenyl)methanone 
• 1027540-54-0 N-(2-Amino-pyridin-3-yl)-2-cyclopropylmethoxy-benzamide 

Relevant academic research and scientific papers

An efficient chromium(iii)-catalyzed aerobic oxidation of methylarenes in water for the green preparation of corresponding acids

A highly efficient method to oxidize methylarenes to their corresponding acids with a reusable Cr catalyst was developed. The reaction can be carried out in water with 1 atm oxygen and K2S2O8as cooxidants, proceeds under green and mild conditions, and is suitable for the oxidation of both electron-deficient and electron-rich methylarenes, including heteroaryl methylarenes, even at the gram level. The excellent result, together with its simplicity of operation and the ability to continuously reuse the catalyst, makes this new methodology environmentally benign and cost-effective. The generality of this methodology gives it the potential for use on an industrial scale. Differing from the accepted oxidation mechanism of toluene, GC-MS studies and DFT calculations have revealed that the key benzyl alcohol intermediate is formed under the synergetic effect of the chromium and molybdenum in the Cr catalyst, which can be further oxidized to afford benzaldehyde and finally benzoic acid.

Oxidative cyclization of alkenoic acids promoted by AgOAc

Alkenoic acids derived from salicylic acid and analogues undergo an unexpected oxidative cyclization process triggered by AgOAc leading to 4H-benzo[d][1,3]dioxin-4-ones. The process is affected by the substitution on the aryl and the allyl units.

SPIRO AMINO COMPOUNDS SUITABLE FOR THE TREATMENT OF INTER ALIA SLEEP DISORDERS AND DRUG ADDICTION

The invention concerns a spiro-amino compound of Formula (Vl) wherein m is 1 or 2 or 3, n is 1 or 2, R is selected from a 5- or 6-membered aromatic ring and a 5- or 6-membered heteroaromatic ring comprising 1 to 3 heteroatoms selected from S, O e N, such ring being substituted with one or two substituents selected from the group consisting of (C1-C3)alkyl, halogen, (C3-C5)cycloalkyloxy, (C1-C3)alkylcarbonyl, phenyl optionally substituted with one or more halogen atoms, a 5- or 6-membered heterocycle comprising at least one nitrogen atom; P is a substituent Q or COQ, wherein Q is selected from the group consisting of phenyl, pyridil, pyrimidil, quinolyl, isoquinolyl, quinoxalyl, benzofuranyl, imidazotriazolyl, being such Q optionally substituted with one or more substituents selected from the group consisting of (C1-C3)alkyl, halogen, trifluoromethyl, carbammido, methylcarbammido, carboxy, methylcarboxy or a pharmaceutically acceptable salt thereof.

COMPOUNDS HAVING A CYCLIC MOIETY AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS

Compounds comprising cyclic moiety and compositions for the delivery of active agents are provided. Methods of administration and preparation are provided as well.

Cyclic Nucleotide Phosphodiesterase Inhibition by Imidazopyridines: Analogues of Sulmazole and Isomazole as Inhibitors of the cGMP Specific Phosphodiesterase

The synthesis and phosphodiesterase (PDE) inhibitory profile of a series of imidazopyridines, including sulmazole and isomazole, on separated PDE isoenzymes are described.The results show that both sulmazole and isomazole are weak inhibitors of PDE III, and their inotropic activity is unlikely to be due to PDE III inhibition alone.Surprisingly, both compounds were found to be significant inhibitors of the cGMP specific isoenzyme, PDE V, and a series of simple 2-substituted phenylimidazopyridines have been made to investigate the SAR of PDE activity.This has been shown to be sensitive to chain length, polarity, and the nature of the heteroatom linking group.Potent PDE V inhibitors, many of which are also significant inhibitors of PDE IV, have been identified.